542 related articles for article (PubMed ID: 28700265)
1. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
Montalban C; Montellano MB; Santos J; Lavis N
Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.
Hu Y; Chu K; Lavis N; Li X; Liang B; Liu S; Shao M; Shu JD; Tabar C; Samson S
Hum Vaccin Immunother; 2019; 15(5):1066-1069. PubMed ID: 30779689
[TBL] [Abstract][Full Text] [Related]
18. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.
Vesikari T; Virta M; Heinonen S; Eymin C; Lavis N; Chabanon AL; Gresset-Bourgeois V
Hum Vaccin Immunother; 2020 Mar; 16(3):623-629. PubMed ID: 31526225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
